LabCompass

Rafael Lancelotta

Psychology · The Ohio State University

Mid career · publishing since 2013

Publications

33

Citations

1,454

Est. group size

~3

Recurring co-author estimate

Active years

14

Publishing since 2013

Research summary
AI-generated

Rafael Lancelotta studies psychedelic compounds, with a particular focus on 5-MeO-DMT (a psychoactive substance found in certain toad secretions and used in some traditional and clinical contexts). His work spans chemical synthesis and characterization of these substances, safety concerns around drug combinations, and studies of their psychological effects, such as changes in life satisfaction, mindfulness, and symptoms of mental health conditions. This research sits at the intersection of pharmacology, toxicology, and clinical psychology.

Psychedelic substances (especially 5-MeO-DMT)Drug safety and toxicologyChemical synthesis of psychoactive compoundsMindfulness and well-being effects of psychedelicsClinical and naturalistic drug-use settings

Publication output has been fairly steady to growing over the last decade, rising from occasional papers in 2017-2018 to a more consistent output of 2-6 papers per year from 2019 onward, with recent years (2024-2025) showing some of the highest counts.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 3.8/year recently
172018: 2 publications182019: 4 publications192020: 5 publications202021: 2 publications212022: 4 publications222023: 2 publications232024: 6 publications6242025: 4 publications252026: 3 publications26
Publishes in
  • Journal of Psychoactive Drugs×5
  • Journal of Psychedelic Studies×3
  • PsycTESTS Dataset×3
  • Psychopharmacology×2
  • Journal of Psychopharmacology×2
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile